Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: a case report
Abstract Background Recent advances in cancer immunotherapy have been remarkable, with many reports on the clinical effects of immune checkpoint inhibitors. Nivolumab has been covered by the national health insurance in Japan as a third-line agent for advanced and recurrent gastric cancer since Sept...
محفوظ في:
| المؤلفون الرئيسيون: | , , , , , , , |
|---|---|
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
BMC
2021-12-01
|
| سلاسل: | Journal of Medical Case Reports |
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://doi.org/10.1186/s13256-021-03200-x |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|